MDxHealth (MDxHealth) Debt-to-Asset : 0.34 (As of Mar. 2024)

View and export this data going back to 2008. Start your Free Trial

What is MDxHealth Debt-to-Asset?

MDxHealth's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $2.21 Mil. MDxHealth's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $38.89 Mil. MDxHealth's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $121.75 Mil. MDxHealth's debt to asset for the quarter that ended in Mar. 2024 was 0.34.

MDxHealth Debt-to-Asset Historical Data

The historical data trend for MDxHealth's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MDxHealth Debt-to-Asset Chart

MDxHealth Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.27

0.50

0.21

0.33

0.32

MDxHealth Quarterly Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.26	0.29	0.30	0.32	0.34

Competitive Comparison of MDxHealth's Debt-to-Asset

For the Diagnostics & Research subindustry, MDxHealth's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MDxHealth's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, MDxHealth's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where MDxHealth's Debt-to-Asset falls into.

MDxHealth Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

MDxHealth's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.123	+	39.142)	/	129.132
	=	0.32

MDxHealth's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.209	+	38.89)	/	121.745
	=	0.34

MDxHealth (NAS:MDXH) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

MDxHealth Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of MDxHealth's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

MDxHealth (MDxHealth) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » MDxHealth SA (NAS:MDXH) » Definitions » Debt-to-Asset

Comparable Companies

BIOQ PSNL VNRX PRE ENZ PRPH ACRS BNR DRIO AWH TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

N/A

Address

Rue d’Abhooz, 31, Cap Business Center, Herstal, Liege, BEL, 4040

Website

https://www.mdxhealth.com

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.